Cantor Fitzgerald Forecasts Stronger Earnings for Septerna

Septerna, Inc. (NASDAQ:SEPN) – Equities researchers at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Septerna in a research note issued to investors on Wednesday, February 19th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($2.40) per share for the year, up from their previous estimate of ($2.58). Cantor Fitzgerald currently has a “Overweight” rating and a $50.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share.

Several other equities research analysts have also commented on the stock. Wells Fargo & Company lowered shares of Septerna from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $43.00 to $14.00 in a research report on Tuesday. TD Cowen assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective on the stock.

Septerna Stock Performance

Shares of NASDAQ SEPN opened at $5.89 on Friday. Septerna has a one year low of $4.17 and a one year high of $28.99. The stock’s fifty day moving average is $18.11.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new position in Septerna in the 4th quarter valued at about $25,000. New York State Common Retirement Fund purchased a new position in Septerna in the 4th quarter valued at about $32,000. Legal & General Group Plc purchased a new position in Septerna in the 4th quarter valued at about $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna in the 4th quarter valued at about $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Septerna in the 4th quarter valued at about $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.